SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Misses Estimates By $0.05 EPS
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) released its earnings results on Wednesday. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.07) by ($0.05), Zacks reports. SAB Biotherapeutics had a negative return on equity of 94.04% and a negative net margin of 1,450.14%. SAB Biotherapeutics Stock Down […]
More Stories
Calamos S&P 500 Structured Alt Protection ETF – September (NYSEARCA:CPST) Now Covered by StockNews.com
StockNews.com started coverage on shares of Calamos S&P 500 Structured Alt Protection ETF – September (NYSEARCA:CPST – Free Report) in...
Qualys (NASDAQ:QLYS) Updates Q4 Earnings Guidance
Qualys (NASDAQ:QLYS – Get Free Report) issued an update on its fourth quarter earnings guidance on Tuesday morning. The company...
Discover Financial Services (NYSE:DFS) Rating Lowered to “Hold” at StockNews.com
StockNews.com lowered shares of Discover Financial Services (NYSE:DFS) from a buy rating to a hold rating in a report issued...
WisdomTree Global ex U.S. Quality Dividend Growth Fund (NYSEARCA:DNL) Trading 2% Higher – Here’s Why
WisdomTree Global ex U.S. Quality Dividend Growth Fund (NYSEARCA:DNL – Get Free Report) shares rose 2% on Thursday . The...
First Trust NASDAQ 100 Ex-Technology Sector Index Fund (NASDAQ:QQXT) Trading 0.6% Higher – What’s Next?
Shares of First Trust NASDAQ 100 Ex-Technology Sector Index Fund (NASDAQ:QQXT – Get Free Report) rose 0.6% on Thursday ....
First Trust United Kingdom AlphaDEX Fund (NASDAQ:FKU) Trading 0.8% Higher – Time to Buy?
First Trust United Kingdom AlphaDEX Fund (NASDAQ:FKU – Get Free Report)’s stock price rose 0.8% on Thursday . The company...